Malignant Peripheral Nerve Sheath Tumors Clinical Trials
2 recruiting trials for Malignant Peripheral Nerve Sheath Tumors. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Malignant Peripheral Nerve Sheath Tumors clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1: 1.
Research is led by Memorial Sloan Kettering Cancer Center (1), Bristol-Myers Squibb (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Selinexor (drug, 1 trial), followed by MRTX1719.
Track Malignant Peripheral Nerve Sheath Tumors trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven...
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Malignant Peripheral Nerve Sheath Tumors, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Malignant Peripheral Nerve Sheath Tumors, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Malignant Peripheral Nerve Sheath Tumors, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.